On February 24, 2026, President Donald Trump strode to the podium for his first State of the Union address of his second term, buoyed by a string of recent policy rollouts and a desire to make health care affordability a centerpiece of his administration’s narrative. With the eyes of the nation fixed on Washington, Trump seized the moment to tout what he cast as a historic breakthrough: a dramatic reduction in prescription drug prices, anchored by his “most favored nation” (MFN) policy and the newly launched TrumpRx.gov platform.
“I’m also ending the wildly inflated cost of prescription drugs like has never happened before,” Trump declared, his words echoing through the chamber. “Other presidents tried to do it, but they never could. They tried. I took prescription drugs, a very big part of health care, from the highest price in the entire world to the lowest. That’s a big achievement. The result is price differences of 300, 400, 500, 600 percent and more, all available right now at a new website called TrumpRx.gov.”
Trump’s claims were nothing short of sweeping. He pointed to Catherine Rayner, a military spouse seated in the audience, as the first user of TrumpRx. According to Trump, Rayner and her husband had struggled with infertility, and a key IVF drug that once cost them $4,000 was now available for under $500 through the website. “She logged on to the TrumpRx website and got that same drug that cost $4,000, got it for under $500,” he said, spotlighting her story as a symbol of the administration’s success.
TrumpRx.gov, launched earlier in February 2026, is a government-hosted platform where Americans can access coupons for more than 40 medications, including popular weight-loss drugs like Ozempic and Wegovy. The discounts, according to the administration, range from 50 to 93 percent off list prices. The site directs users to drugmakers’ direct-to-consumer websites and provides coupons that can be presented at pharmacies. Dr. Mehmet Oz, administrator of the Centers for Medicare and Medicaid Services, has been a vocal champion of the initiative, predicting that lower prices for drugs like Ozempic and Wegovy would help the country collectively lose 100 million pounds this year. “We’re going to have a lot of Trump babies with these costs,” Oz quipped, referencing the projected increase in fertility treatments made more affordable by the program.
But beneath the fanfare, skepticism has bubbled from multiple quarters. Health policy experts and economists have noted that while the TrumpRx platform might provide relief for certain medications not commonly covered by insurance, many of the drugs featured already have generic alternatives available at even lower prices. A STAT analysis found that the majority of brands on TrumpRx could be sourced as generics elsewhere, raising questions about the program’s real-world impact for most Americans. The site itself includes a disclaimer that prices “may be even lower” for those with insurance, as it lists out-of-pocket costs rather than insured rates.
Trump’s prescription drug strategy is part of a broader effort to reframe the Republican approach to health care ahead of the midterm elections. The president has leaned into policies that poll well with voters—nutrition and drug prices—while steering clear of more divisive topics. His “Great American Health Plan,” unveiled in January, retools the administration’s message to focus on affordability and consumer empowerment. In his address, Trump also floated the idea of redirecting government funding from health insurance companies to health savings accounts, giving individuals more direct control over their medical spending. “I want to stop all payments to big insurance companies and instead give that money directly to the people,” he said, echoing a long-standing Republican critique of the Affordable Care Act’s premium subsidies.
Yet, the president’s promises have met with resistance from several directions. Democrats and left-leaning advocacy groups, like Protect Our Care, have countered Trump’s narrative with their own. “Premiums are skyrocketing, drug prices are outrageous, and hard-working people are being crushed under the weight,” said Brad Woodhouse, CEO of Protect Our Care, in a statement released ahead of the speech. “No amount of showmanship during the State of the Union can erase the reality millions are facing at their kitchen tables.” Democrats have made health care affordability central to their campaign messaging, highlighting the expiration of enhanced Affordable Care Act tax credits that sent premiums soaring for millions earlier this year.
Republican lawmakers, meanwhile, have shown reluctance to fully embrace Trump’s MFN pricing policy. The pharmaceutical industry’s leading trade group, PhRMA, has voiced strong opposition, warning that “government-imposed Most Favored Nation policies would undermine U.S. competitiveness while doing nothing to address insurance practices that deny care and raise costs for patients.” Stephen Ubl, PhRMA’s CEO, argued that such policies would siphon billions from American research and development, slow the pace of new cures, and increase reliance on foreign innovation, particularly from China. In contrast, CMS Administrator Mehmet Oz has argued that MFN legislation would actually protect drugmakers from future administrations pressing for even lower prices, highlighting the complexity of the debate within the industry itself.
Despite the controversy, Trump called directly on Congress to codify his MFN pricing policy into law, addressing Senate Majority Leader John Thune and House Speaker Mike Johnson by name. “It’s going to be very hard for somebody that comes along after me to say, ‘Let’s raise drug prices by 700 or 800%.’ But John and Mike, if you don’t mind, codify it,” he urged. However, Axios reported that there have been no signs of significant legislative activity on Capitol Hill to advance Trump’s drug pricing deals or his broader health care plan, with many Republicans wary of the potential political fallout if promised savings don’t materialize for everyday Americans.
Trump’s address also touched on other health policy flashpoints. He renewed his administration’s crackdown on fraud in federal health and child care programs, with Vice President JD Vance now leading investigations in Minnesota, Maine, and California. The administration has particularly targeted Minnesota, linking fraud to the state’s Somali immigrant population—a claim that has drawn sharp denials from state officials. Trump also reiterated his opposition to gender-affirming care for young people, touting a raft of executive orders, Department of Justice subpoenas, and proposed rule changes aimed at restricting access to such care. These efforts have already led dozens of institutions to limit or end gender-affirming treatments for youth since January 2025, though many of the administration’s moves remain tied up in legal challenges.
Noticeably absent from the speech were mentions of vaccine policy—an issue that has sparked heated debate within the administration and among public health experts. In December, Trump ordered an overhaul of the childhood vaccine schedule, and Health Secretary Robert F. Kennedy Jr. later announced cuts to recommended pediatric vaccines. The administration has also slashed funding and staffing at agencies like the FDA, CDC, and NIH, moves that have slowed grantmaking and raised questions about the nation’s scientific capacity.
As the dust settles from Trump’s marathon State of the Union address—the longest since 1964, according to The American Presidency Project—Americans are left to weigh the promises against the realities. While the administration’s efforts to lower drug prices have garnered headlines and offered hope to some, the broader impact remains uncertain, with political and industry opposition clouding the path forward. For now, the TrumpRx experiment stands as a symbol of both the possibilities and the limitations of presidential power in reshaping the nation’s health care landscape.